Saturday, December 3, 2022

561.316.3330

Biotechnology News Magazine

MP Biomedicals Launches New Line of Well-characterized Antibodies, antigens, & ELISA Kits to Advance SARS-CoV-2 Research

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

MP Biomedicals, LLC has recently expanded its portfolio of COVID-19-related research products to include a wide selection of highly pure SARS-CoV-2 recombinant proteins, monoclonal antibodies specific and potent against a variety of SARS-CoV-2 protein domains, and high-quality ELISA kits to quantify SARS-CoV-2 and the virus-triggered human IgM and IgG antibodies.

The disease COVID-19, caused by SARS-CoV-2 virus infection, continues to impact public health on a global scale. With new variants rapidly emerging, it is critical that scientists have access to the latest research tools. MP Biomedicals’ extensive line of SARS-CoV-2 research products are fully validated to ensure quality and performance to help advance COVID-19 research.

“Our new collection of COVID-19-related research products is another big step towards our goal of providing researchers with innovative, quality solutions,” said Dr. Xiao-wei Wang, Immunology Product Manager, MP Biomedicals. “We will continue to expand our portfolio and offerings to do our part in addressing the current needs of the scientific community.”

To learn more about MP Biomedicals’ COVID-19 research products, please visit www.mpbio.com/sars-cov-2-research.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine